News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities
Author(s)Cynthia A. Challener
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Advertisement
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Download
.
Articles in this issue
over 11 years ago
Potential Benefits Drive Interest in Continuous Manufacturingover 11 years ago
Continuous Bioprocessing Challengesover 11 years ago
Optimizing the Sterilization of Liquids in Sealed Containersover 11 years ago
Using Modular Systems in Biopharmaceutical Manufacturingover 11 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsover 11 years ago
Single-Use Technology in Parenteral Fill/FinishNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
AI and Human Collaboration Essential for Bio/pharma Innovation
4
Why Sound Science Is Pharma's Best Defense Against Regulatory Shifts
5
